RNAi News and Research

RSS

Repurposed gout medication (probenecid) shows potent inhibition of SARS-CoV-2 replication

New research by a team of scientists in the USA describes the potential utility of a drug called probenecid, commonly used to treat gout, to treat this devastating viral illness caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) – the causative virus of COVID-19.

25 May 2021

Interfering RNA nanoparticles could be a potential COVID-19 therapy

Study shows lipid nanoparticle-based siRNA is potent in suppressing severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) – the causative agent of coronavirus disease 2019 (COVID-19) – in cells as well as in mice models.

21 Apr 2021

Researchers examine SARS-CoV-2 RNA interactome

A new study focuses on the identification of RNA-binding protein by mass spectrometry (ChIRP-M/S) approach. This study develops a global map that contains the complete set of host proteins that involve the SARS-CoV-2 genome during infection. This study has successfully identified new SARS-CoV-2 host dependency factors by merging proteomics data with gene silencing experiments. Such a discovery has paved new roads to develop more antiviral therapies.

25 Mar 2021

Researchers develop non-cereal crop to enhance yields and consumer health

Delivering the benefits of agricultural biotechnology to smallholder farmers requires that resources be directed toward staple food crops.

17 Feb 2021

COVID-19 pandemic and nanotechnology

Writing in the International Journal of Nanomedicine, Professor Dongki Yang, from the Department of Physiology, Gachon University, South Korea, has reviewed the available knowledge on the coronaviruses, current approaches to tackle the newly emerged SARS-CoV-2 infection, and the innovative application of nanotechnology in the COVID-19 pandemic.

8 Feb 2021

New research on small non-coding RNAs and SARS-CoV-2

A recently published mini-review in the Frontiers in Microbiology on the altered expression of small non-coding RNAs during coronavirus-mediated infections.

26 Oct 2020

Two studies shed light on the biology and potential vulnerabilities of schistosomes

Two studies led by UT Southwestern researchers shed light on the biology and potential vulnerabilities of schistosomes - parasitic flatworms that cause the little-known tropical disease schistosomiasis.

24 Sep 2020

Vesigen Therapeutics to develop and commercialize novel drug-delivery technologies

Harvard University's Office of Technology Development (OTD) and the Harvard T.H. Chan School of Public Health today announced the launch of Vesigen Therapeutics, a startup company that aims to overcome the challenge of delivering next-generation therapeutics, such as gene-editing complexes, RNA molecules, and other large proteins, to intracellular targets in specific tissues of interest.

23 Jul 2020

siRNA therapeutics can reduce off-target side effects of anticancer drugs

Small interfering RNA (siRNA) has shown tremendous potential for treating human diseases in the past decades.

9 Jul 2020

Entos Pharmaceuticals selects two lead DNA vaccine candidates for COVID-19

Entos Pharmaceuticals, a healthcare biotechnology company developing nucleic acid medicines with its Fusogenix drug delivery platform, today announced the selection of two lead candidates for a pan-coronavirus Fusogenix DNA vaccine from its prototyping program launched at the onset of the global COVID-19 pandemic.

25 Jun 2020

Drug offers hope for patients with primary hyperoxaluria type 1

Primary hyperoxaluria type 1 (PH1) is an autosomal recessive inherited disorder that begins in childhood and adolescence.

8 Jun 2020

Gene discovery in fruit flies could lead to treatments for age-related hearing loss

Scientists at UCL have discovered sets of regulatory genes, which are responsible for maintaining healthy hearing. The finding, made in fruit flies, could potentially lead to treatments for age-related hearing loss (ARHL) in humans.

2 Jun 2020

RNA interference machinery influences epithelial cell biology

Epithelial cells are held together and connected by several different types of structures that form cell-cell contacts.

9 May 2020

Epivax and Entos Pharmaceuticals to develop DNA-based vaccine for COVID-19

Entos Pharmaceuticals (Entos), a healthcare biotechnology company that develops next generation nucleic acid medicines using the Fusogenix drug delivery platform, today announced a collaboration with EpiVax, Inc. (EpiVax), a world leading informatics and immunology biotechnology company with a proven track record in vaccine development.

28 Apr 2020

Study identifies novel anti-aging targets

A recent study published in Nature has reported two conserved epigenetic regulators as novel anti-aging targets.

26 Feb 2020

Researchers identify key modifier in large genetic deletion linked to neurodevelopmental disorders

Neurodevelopmental disorders, including schizophrenia and autism, likely result from complex interactions that modify the effects of individual genes.

16 Feb 2020

MGH researchers uncover potential antiviral drug target for treating infectious diseases

As the coronavirus outbreak shows, viruses are a constant threat to humanity. Vaccines are regularly developed and deployed against specific viruses, but that process takes a lot of time, doesn't help everyone who needs protection, and still leaves people exposed to new outbreaks and new viruses.

11 Feb 2020

Study shows how gene therapy may help protect against vision loss in multiple sclerosis

New research by Dorothy P. Schafer, PhD, at the University of Massachusetts Medical School, reveals the molecular process in which synaptic connections in the brain are damaged in multiple sclerosis and how this contributes to neurodegenerative symptoms.

21 Jan 2020

Entos Pharmaceuticals signs new collaboration agreement with biopharmaceutical company

Entos Pharmaceuticals Inc. ("Entos" or the "Company"), a healthcare biotechnology company focused on the development of next-generation nucleic acid-based therapies using their Fusogenix drug delivery platform, today announced it has entered into a research, development and collaboration agreement ("Agreement") with a clinical stage biopharmaceutical company ("Partner") focused on the development of novel therapeutic compounds targeting autoimmune and inflammatory diseases.

3 Oct 2019

CRISPR may explain why so many experimental cancer drugs fail

Scientists have used CRISPR–Cas9 to investigate how ten cancer drugs interact with their protein target, revealing some intriguing findings.

13 Sep 2019